

# Cells Expressing BRAF<sup>V600E</sup> have a unique lipid profile

Emily Paton<sup>1a</sup>, Jacqueline Turner<sup>1a</sup>, William Robinson, MD, PhD<sup>1</sup>, Kasey Coutts, PhD<sup>1</sup>, Isabel Schlaepfer, PhD<sup>1</sup>

1. University of Colorado Department of Medicine, Division of Medical Oncology

a. These authors contributed equally

## Abstract

There is increasing evidence that oxidative metabolism and fatty acids play an important role in BRAF-driven tumorigenesis, yet the effect of BRAF<sup>V600E</sup> expression on metabolism is poorly understood. We examined how this BRAF mutation modulates metabolite abundance. Using NIH3T3 mouse fibroblast models, we found cells expressing BRAF<sup>V600E</sup> were enriched with immunomodulatory lipids and had a unique transcriptional signature. The BRAF<sup>V600E</sup> mutation promoted accumulation of long chain polyunsaturated fatty acids and rewired metabolic flux with non-Warburg behavior. This cancer-promoting mutation induced the formation of TNT-like protrusions which preferentially accumulated lipid droplets. In the plasma of melanoma patients harboring the BRAF<sup>V600E</sup> mutation, levels of lysophosphatidic acid, sphingomyelin, and long chain fatty acids were significantly increased in patients who did not respond to BRAF inhibitor therapy following treatment. Our findings show BRAF<sup>V600E</sup> status plays an important role in regulating the immunomodulatory lipid profile and lipid trafficking which may inform future therapy across cancers.